Navigation Links
'Different kind of stem cell' possesses attributes favoring regenerative medicine
Date:11/19/2012

WASHINGTON -- A research team at Georgetown Lombardi Comprehensive Cancer Center say the new and powerful cells they first created in the laboratory a year ago constitute a new stem-like state of adult epithelial cells. They say these cells have attributes that may make regenerative medicine truly possible.

In the November 19 online early edition of the Proceedings of the National Academy of Sciences (PNAS), they report that these new stem-like cells do not express the same genes as embryonic stem cells and induced pluripotent stem cells (iPSCs) do. That explains why they don't produce tumors when they grow in the laboratory, as the other stem cells do, and why they are stable, producing the kind of cells researchers want them to.

"These seem to be exactly the kind of cells that we need to make regenerative medicine a reality," says the study's senior investigator, chairman of the department of pathology at Georgetown Lombardi, a part of Georgetown University Medical Center.

This study is a continuation of work that led to a breakthrough in December 2011 when Schlegel and his colleagues demonstrated that he and his team had designed a laboratory technique that keep both normal as well as cancer cells alive indefinitely which previously had not been possible.

They had discovered that adding two different substances to these cells (a Rho kinase inhibitor and fibroblast feeder cells) pushes them to morph into stem-like cells that stay alive indefinitely. When the two substances are withdrawn from the cells, they revert back to the type of cell that they once were. They dubbed these cells conditionally reprogrammed cells (CRCs).

The advance was seen as an exciting demonstration of personalized cancer medicine. In fact, a case study authored by Schlegel and his team, reported in the September 27 issue of the New England Journal of Medicine (NEJM), demonstrated how CRCs derived from normal and tumor cells of a 24-year-old man with a rare type of lung tumor allowed physicians to identify an effective cancer therapy. These cells were used to screen potential treatments and in this way, the scientists were able to see which therapies were active against the tumor cells and less harmful to the normal cells.

"Our first clinical application utilizing this technique represents a powerful example of individualized medicine," Schlegel said in September. But he cautioned, "It will take an army of researchers and solid science to figure out if this technique will be the advance we need to usher in a new era of personalized medicine."

This study was designed to see how the CRCs compared to known properties of embryonic stem cells and iPSCs, which are adult cells that have been manipulated by addition of genes to make them capable of differentiating (morphing into new adult cell types). Both embryonic stem cells and iPSCs have been investigated for use in regenerative medicine, but each can form tumors when injected into mice and "it is difficult to control what kind of cells these cells differentiate into," Schlegel says. "You may want them to be a lung cell, but they could form a skin cell instead."

In contrast, cells derived from the lung will develop stem-like properties when the conditions are added, allowing expansion of the lung cell population. However, when the conditions are withdrawn, they will revert to differentiated lung cells, he says. Schlegel added that they do this rapidly within three days of adding the inhibitor and feeder cells, they efficiently generated large numbers of stem-like cells. It is also completely reversible: when the conditions are taken away, the cells lose their stem-like properties and potentially can be safely implanted into tissue.

The researchers compared gene expression between the three cell types and found that while some of the same genes are expressed in all the cells, CRCs don't over express the same critical genes that embryonic stem cells and iPSCs do. "Because they don't express those genes, they don't form tumors and they are lineage committed, unlike the other cells," Schlegel says. "That shows us that CRCs are a different kind of stem-like cell."

As part of the study, the research team showed that when cervical cells are conditioned and placed on a three-dimensional platform, they start to form cells that "look like the cervix," Schlegel says. The same is true from cells in the trachea on a 3-D platform, they begin to look like a trachea, he says.

If and when use of CRCs are perfected for the clinic and that will take considerable work, Schlegel says they potential could be used in a wide variety of novel ways.

"Perhaps they could be used more broadly for chemosensitivity, as we demonstrated in the NEJM study, for regenerative medicine to replace organ tissue that is damaged, for diabetes we could remove remaining islet ells in the pancreas, expand them, and implant them back into the pancreas and to treat the many storage diseases caused by lack of liver enzymes. In those cases, we can take liver cells out, expand them and insert normal genes in them, and put them back in patients," Schlegel says.

"The potential of these cells are vast, and exciting research to help define their ability is ongoing," he says.


'/>"/>

Contact: Karen Mallet
km463@georgetown.edu
Georgetown University Medical Center
Source:Eurekalert

Related medicine news :

1. Study shows different approach after progression in non-small cell lung cancer patients
2. New Diabetes Drugs Have Different Advantages, Study Says
3. Hearing impaired ears hear differently in noisy environments
4. Teens tell different tales about themselves depending on gender
5. Men, Women Do See Things Differently: Study
6. Womens Brains React Differently Than Mens to Alcoholism, Study Finds
7. More clues about why chimps and humans are genetically different
8. Hey, I’m over here: Men and women see things differently
9. Marriage has different meanings for blacks and whites
10. Cell differentiation as a novel strategy for the treatment of an aggressive type of skin cancer
11. UK cyclists take different paths
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/21/2017)... , ... July 21, 2017 , ... ... received a $5,000 grant from the C. R. Bard Foundation, Inc. ... at Somerset Hills , a service available through the nonprofit home care agency. ...
(Date:7/21/2017)... ... July 21, 2017 , ... In the first ... the Multicenter Orthopaedics Outcome Network (MOON) demonstrated that patients could perform sports-related functions ... activity levels decline over time. The study, presented today at the American ...
(Date:7/20/2017)... ... July 20, 2017 , ... Acute myeloid leukemia (AML) ... progresses rapidly without treatment. Newly diagnosed patients face intense chemotherapy regimens and a ... relapse. With such a challenging diagnosis that requires immediate action, patients and ...
(Date:7/20/2017)... ... 20, 2017 , ... Team Type 1 Foundation, a nonprofit organization pursuing a ... diabetes, is teaming up with a Microsoft Corp. employee-led hackathon team for the 2017 ... , “Team Type 1’s mission overlaps seamlessly with Microsoft’s mission to empower every ...
(Date:7/20/2017)... ... 2017 , ... The Dermatology Clinic announced today the addition of Dr. Scott ... from LSU, graduating summa cum laude. He attended Emory University School of Medicine in ... Louis, Dr. Dunbar moved to New York to complete an AGCME-accredited Mohs surgery fellowship ...
Breaking Medicine News(10 mins):
(Date:7/11/2017)... Ill. , July 11, 2017  Sysmex ... and urinalysis diagnostic testing equipment as well as ... innovation: a way to make quality assurance easier ... processes. "Sysmex is well known for the innovation ... Quality Monitor elevates quality assurance processes to ...
(Date:7/11/2017)... 2017 Oramed Pharmaceuticals Inc. (NASDAQ: ... focused on the development of oral drug delivery systems, ... (FDA) has agreed to schedule an End-of-Phase II meeting ... of its oral insulin capsule ORMD-0801 in the treatment ... primary and secondary endpoints by indicating a statistically significant ...
(Date:7/10/2017)... July 10, 2017 The Institute for In ... is the recipient of a VITROCELL® inhalation exposure system ... Science Consortium. The device, which is designed to replace ... human lung cells to airborne test materials in an ... the VITROCELL® system for testing combustible tobacco products, as ...
Breaking Medicine Technology: